Q BioMed, Inc. operates as a biomedical acceleration and development company. It focuses on acquiring and in-licensing pre-clinical, clinical-stage and approved life sciences therapeutic products. Its products include Strontium-89, MetastronTM, QBM-001, Uttroside-B, and MAN 01. The company was founded by Enrique Navas on November 22, 2013 and is headquartered in New York, NY.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company